Edition:
United Kingdom

ICON PLC (ICLR.OQ)

ICLR.OQ on NASDAQ Stock Exchange Global Select Market

111.18USD
11 Dec 2017
Change (% chg)

$-0.73 (-0.65%)
Prev Close
$111.91
Open
$111.63
Day's High
$112.53
Day's Low
$110.88
Volume
134,122
Avg. Vol
98,187
52-wk High
$124.33
52-wk Low
$73.76

Summary

Name Age Since Current Position

Ciaran Murray

53 2017 Chairman of the Board

Steve Cutler

54 2017 Chief Executive Officer, Director

Brendan Brennan

36 2012 Chief Financial Officer

Diarmaid Cunningham

40 2014 Executive Vice President, General Counsel, Secretary

Hugh Brady

57 2014 Non-Executive Director

John Climax

62 2010 Non-Executive Director

Joan Garahy

54 2017 Non-Executive Director

William Hall

65 2013 Non-Executive Director

Ronan Lambe

75 2002 Non-Executive Director

Eugene McCague

2017 Non-Executive Director

Mary Pendergast

66 2014 Non-Executive Director

Dermot Kelleher

59 2008 Non-Executive Independent Director

Simon Holmes

IR Contact Officer

Biographies

Name Description

Ciaran Murray

Mr. Ciaran Murray has been appointed as Chairman of the Board of the Company., effective as of 1st March 2017. He was Chief Executive Officer, Executive Director of Icon PLC. Mr. Murray is an executive with 30 years of leadership experience forged from a career spent operating in global markets in high-growth entrepreneurial companies and blue-chip multi-nationals, including PricewaterhouseCoopers, Kraft Foods, Novell Inc., Northern Foods and Codec DCC. Mr. Murray has also played a leadership role in advocating for safe, ethical high-quality research through his 2014 Chairmanship of the Association of Clinical Research Organisations (ACRO). ACRO represents the CRO industry globally to key stakeholders including pharmaceutical, biotech and medical device companies, regulators, legislators and patient groups. In 2014 Mr. Murray was named as a leader in CRO Innovation by PharmaVOICE100, a listing of the most influential people in the biopharma industry. Mr. Murray graduated with a Bachelor of Commerce degree from University College Dublin and he is a Fellow of the Institute of Chartered Accountants in Ireland. He was awarded an Honorary Degree of Doctor of Laws from University College Dublin in 2013 for his support of third level research and innovation in Ireland.

Steve Cutler

Dr. Steve Cutler has been appointed as Chief Executive Officer, Director of the Company., effective as of 1st March 2017. He was Chief Operating Officer, Director of the Company. Dr. Cutler joined ICON in 2011 as Group President, ICON Clinical Research Services. Dr. Cutler successfully led this business to significant growth and, as a result, was promoted to Chief Operating Officer in January 2014. As Chief Operating Officer, Dr. Cutler has responsibility for all of ICON's operational service areas, including clinical research, early phase, laboratories, DOCS resourcing and commercialisation and outcomes. Dr. Cutler's operational leadership as Chief Operating Officer has helped ICON successfully deliver innovative and integrated services and solutions to customers. Prior to joining ICON, Dr. Cutler was Chief Executive Officer of Kendle. Prior to Kendle, Dr. Cutler held various senior roles in both Quintiles and Sandoz (now Novartis). Dr. Cutler holds a B.Sc. and a Ph.D from the University of Sydney and a Masters of Business Administration from the University of Birmingham (UK).

Brendan Brennan

Mr. Brendan Brennan is Chief Financial Officer of Icon PLC. Mr. Brennan joined ICON in 2006 and he has served in a number of senior finance roles in the Company including the role of Senior Vice President of Corporate Finance. Prior to this he developed his corporate finance experience in Cement Roadstone Holdings, a major Irish building materials organization. Mr. Brennan qualified as a chartered accountant with PricewaterhouseCoopers and obtained a bachelors degree in Accounting and Finance from Dublin City University

Diarmaid Cunningham

Mr. Diarmaid Cunningham was General Counsel, Executive Vice President and Company Secretary of Icon PLC. Mr. Cunningham joined the Company in November 2009 and was appointed Company Secretary in October 2011. Mr Cunningham spent 10 years with A&L Goodbody, one of Ireland's premier corporate law firms, prior to joining the Company. Mr. Cunningham graduated with a Bachelor of Business and Legal Studies from University College Dublin in 1997 and qualified as a lawyer with A&L Goodbody in 2001. Mr. Cunningham served as Secretary to the Board of the Association of Clinical Research Organisations (ACRO) in 2013 and 2014. ACRO represents the CRO industry globally to key stakeholders including pharmaceutical, biotech and medical device companies, regulators, legislators and patient groups

Hugh Brady

Dr. Hugh Brady is Non-Executive Director of the Company. Dr. Brady is President Emeritus of University College Dublin (UCD), one of Europe’s leading research-intensive universities, where he served as President from 2004 until the end of 2013. During his tenure Dr. Brady oversaw a significant expansion of UCD’s science, engineering and biomedical research capacity, including the development of the Conway Institute for Biomedical Research, UCD Clinical Research Centre and the Dublin Academic Medical Centre. In addition, he led a major growth in UCD’s international footprint, including the establishment of the Beijing-Dublin International College and the UCD Shenzhen Health Sciences Institute in China. A nephrologist by training, Dr. Brady was Professor of Medicine and Therapeutics at UCD before being appointed the university’s President. He returned to Ireland having built a successful career as a physician and biomedical research scientist in the US, where he spent nine years at Harvard University, including a period as Associate Professor of Medicine. In parallel with his academic career at Harvard, he served as Director of the Renal Division of the Brockton/West Roxbury VA Medical Center and Consultant Physician at the Brigham and Women’s Hospital, Boston. He has an international reputation in the pathogenesis of diabetic kidney disease and renal inflammation.

John Climax

Dr. John Climax is Non-Executive Director of Icon PLCFrom January 2010 he has held a position as an outside director of the Company. Dr. Climax has over 25 years of experience in the contract research industry. Dr. Climax is the Executive Chairman of Dignity Sciences Ltd. Dr. Climax received his primary degree in pharmacy in 1977 from the University of Singapore, his masters in applied pharmacology in 1979 from the University of Wales and his Ph.D. in pharmacology from the National University of Ireland in 1982. He has authored a significant number of papers and presentations, and holds adjunct professorship at the Royal College of Surgeons of Ireland.

Joan Garahy

Ms. Joan Garahy serves as Non-Executive Director of the Company. Ms. Garahy is the managing director of ClearView Investment & Pensions Limited, a financial advisory company. Ms. Garahy is also a non-executive director of both Kerry Group plc and Irish Residential Properties REIT plc. Ms. Garahy's previous executive roles include founder and managing director of HBCL Investment & Pensions Ltd, director of investments at HC Financial Services Group, head of research at the Irish National Pension Reserve Fund, head of research at Hibernian Investment Managers and her equity analyst roles with Goodbody Stockbrokers and NCB Group. Ms. Garahy was also previously a non-executive director of Galway University Foundation and she is currently a member of the board of The Irish Chamber Orchestra. Ms. Garahy holds a Bachelor of Science degree from University College Galway and a Master of Science from University College Dublin.

William Hall

Professor Doctor William W. Hall, M.D., Ph.D. has served as Non-Executive Director of Icon PLC since February 21, 2013. He is a renowned expert in infectious diseases and virology, is Chair of Medical Microbiology and Director of the Centre for Research in Infectious Diseases at University College Dublin’s (UCD) School of Medicine and Medical Science. He is also a director of UCD’s National Virus Reference Laboratory and is a consultant microbiologist at St. Vincent’s University Hospital Dublin. Professor Hall also serves as a consultant to the Minister of Heath and Children in the Republic of Ireland, providing input on a number of topics including influenza pandemic preparedness and bioterrorism. Prior to his tenure at UCD, Professor Hall was Professor and Head of the Laboratory of Medical Virology, Senior Physician and Director of the Clinical Research Centre at the Rockefeller University in New York. He previously served as an Assistant and Associate Professor of Medicine at Cornell University. Professor Hall is a board member of The Atlantic Philanthropies and is a co-founder of the Global Virus Network.

Ronan Lambe

Dr. Ronan Lambe, Ph.D., is Non-Executive Director of Icon PLC. He has served as an outside director of the Company since January 2008. Dr. Lambe has over 30 years of experience in the contract research industry. Dr. Lambe attended the National University of Ireland where he received his Bachelor of Science degree in chemistry in 1959, his masters in biochemistry in 1962 and his Ph.D. in pharmacology in 1976.

Eugene McCague

Mr. Eugene McCague is Non-Executive Director of the Company. Mr. McCague was a corporate partner of Arthur Cox, one of Ireland's premier law firms, from 1988 until June 2017. During his time with Arthur Cox, Mr. McCague served as both managing partner and chairman of Arthur Cox and also advised a wide range of public and private companies on mainstream corporate work, mergers and acquisitions, corporate restructurings and corporate governance. In addition to his distinguished legal career, Mr. McCague also has extensive board experience with commercial, government and educational organizations. Mr. McCague currently serves on the board of FLY Leasing Limited, an aircraft leasing company listed on the New York Stock Exchange, and on the board of the Irish branch of AON Insurance. He also serves as chairman of the governing authority of University College Dublin. Mr. McCague's previous board roles include the Health Service Executive, the Irish state body which administers public health service in Ireland, chairman of the governing body of Dublin Institute of Technology and chairman of the Dublin Institute of Technology Foundation. Mr. McCague was also president of the Dublin Chamber of Commerce in 2006. Mr. McCague holds a Bachelor of Civil Law degree and a diploma in European Law from University College Dublin.

Mary Pendergast

Ms. Mary Pendergast, J.D., LL.M. is Non-Executive Director of Icon Public Limited Company. She is an expert in the regulatory aspects of drug development and is President of Pendergast Consulting, a consulting firm that advises biopharmaceutical companies, patient groups, professional and advocacy organisations, governments and academic and financial institutions. Prior to founding her own firm, Ms. Pendergast was Executive Vice President of Government Affairs at Elan Corporation plc from 1998 to 2003. Ms. Pendergast also spent more than 18 years at the US Food and Drug Administration (FDA), serving as Deputy Commissioner and Senior Advisor to the FDA Commissioner and Associate Chief Counsel for Enforcement. Ms. Pendergast is also a board member of Impax Laboratories, Inc.

Dermot Kelleher

Professor Dermot Kelleher is Non-Executive Independent Director of Icon PLC. Professor Kelleher is currently Vice President (Health) and Dean of the Faculty of Medicine at Imperial College London. From 2004 to 2012 he was Head of the School of Medicine and Vice Provost for Medical Affairs at Trinity College, Dublin, Ireland where he led the development of the Institute of Molecular Medicine and Molecular Medicine Ireland. His research interests have focused on gastrointestinal infectious and inflammatory diseases and over a distinguished thirty year career he has led significant research projects in this field. Alongside his notable academic appointments he has served as a visiting research scientist with a major pharmaceutical company and has been a founder of a number of biotechnology companies.

Simon Holmes